Health
Merck and GPHL Collaborate on Business Innovation and Development in the Greater Bay Area
GUANGZHOU, China, March 2, 2021 /PRNewswire/ -- Merck, a leading science and technology company, today signed a Memorandum of Understanding (MOU) to begin strategic collaboration with Guangzhou Pharmaceutical Holdings Limited (GPHL), China's leading pharmaceutical company. The collaboration aim...
2021-03-02 18:12
3416
Cipla receives final approval for generic version of GlaxoSmithKline's IMITREX® (Sumatriptan Nasal Spray, 20 mg)
MUMBAI, India, March 2, 2021 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereinafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the United States Food and Drug...
2021-03-02 16:01
4425
Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug
STOCKHOLM, March 2, 2021 /PRNewswire/ -- Oscotec Inc. (039200: KOSDAQ), the Korean drug development company, and Beactica Therapeutics AB, the Swedish drug discovery company, today announced a new research development and licensing agreement. Oscotec and Beactica will initially jointly collaborat...
2021-03-02 15:21
1337
CMAB Biopharma Congratulates QureBio on FDA Clearance of IND Application for Claudin18.2/PD-L1 Bispecific Antibody
SUZHOU, China, March 2, 2021 /PRNewswire/ -- Recently, CMAB Biopharma (Suzhou) Inc's ("CMAB") partner QureBio Ltd ("QureBio") has announced its innovative drug Q-1802 received United States Food and Drug Administration (FDA) clearance for an Investigational New Drug (IND) application. This applic...
2021-03-02 13:43
1541
Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB
SYDNEY, March 2, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB (STO: OASM), an innovation-focuse...
2021-03-02 07:00
4307
INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18
Trial achieved primary and secondary efficacy endpoints among all evaluable subjects in the Phase 3 multi-center, randomized, double-blind, placebo-controlled trial VGX-3100 is the first DNA medicine to achieve efficacy endpoints in a Phase 3 clinical trial INOVIO also continues to partner with...
2021-03-02 05:05
4947
New NCCN Guidelines for Histiocytosis Clarify Best Practices for Recently-Defined Cancers
New clinical practice guidelines from National Comprehensive Cancer Network focus on workup and management for three main adult histiocytic disorders. PLYMOUTH MEETING, Pa., March 1, 2021 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers —tod...
2021-03-01 21:35
1555
China Biologic Announces Shareholders' Approval of Merger Agreement
BEIJING, March 1, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that, at an extraordinary general meeting (the "EGM") held today, the Company...
2021-03-01 21:00
10019
BioVaxys Expanding Technology Platform To Address Emerging SARS-CoV-2 Variants
BVX-0320 and Covid-T to have capability to address UK, Brazilian and South African Virus Variants VANCOUVER, B.C., March 1, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF)("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer app...
2021-03-01 21:00
4766
Frost & Sullivan Reveals Virtual Care's Enormous Potential in the United States
The US virtual care market is expected to witness more than a seven-and-a-half-fold growth by 2025, with a CAGR of 40.4% SANTA CLARA, Calif., March 1, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis, COVID-19 Pandemic Ignites Enthusiasm for Virtual Care, finds that virtual care is the ne...
2021-03-01 20:02
1372
Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development
SUZHOU, China, March 1, 2021 /PRNewswire/ -- Suzhou Medilink Therapeutics Ltd. (Medilink), a global biotech company focusing on next-generation antibody-drug conjugate Research & development, announced the closing of a$50 million series A financing, to accelerate its innovative pipeline developme...
2021-03-01 19:50
4723
CARsgen Therapeutics Receives Orphan Medicinal Product Designation from the European Medicines Agency for CT041 CLDN18.2 CAR T Cells for the Treatment of Gastric Cancers
SHANGHAI, March 1, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited, a clinical-stage biopharmaceutical company, today announced that the European Commission (EC) has granted orphan designation for CT041, CARsgen's first-in-class Claudin 18.2 (CLDN18.2) targeted CAR-T product candidate ...
2021-03-01 19:00
3675
Merck Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant
- Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care - A Phase II trial reported that xevinapant plus che...
2021-03-01 18:48
2500
TVM Capital Healthcare Exits Cambridge Medical and Rehabilitation Center for US$ 232 Million, a 4.6x Return on Capital Invested
SINGAPORE, March 1, 2021 /PRNewswire/ -- TVM Capital Healthcare, a global specialist healthcare private equity firm operating in emerging markets, announces the successful sale of its portfolio company Cambridge Medical and Rehabilitation Center ("CMRC") to UAE-based publicly traded investment c...
2021-03-01 16:18
3074
Avalon SteriTech and SoftBank Robotics Group Launch New Joint Venture to Develop and Promote Innovative Public Healthcare and Hygiene Solutions
HONG KONG, March 1, 2021 /PRNewswire/ -- Avalon SteriTech Limited ("Avalon") and SoftBank Robotics Group ("SBRG") today announced a joint venture focusing on the development of innovative products and technologies that strive to empower and benefit public health and well-being. The joint venture ...
2021-03-01 13:00
1845
Everest Medicines Announces Selection as a Constituent of Certain Indexes of Hang Seng Indexes Company Limited
SHANGHAI, March 1, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater China and other parts of Asia, today announced t...
2021-03-01 12:36
4553
Sciwind's Investigational New Drug Approved for NASH Trial
HANGZHOU, China, March 1, 2021 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd., (Sciwind), a clinical-stage, fast-growing biotech focusing on research and development of innovative biologics, today announced that XW003, a potential candidate for the treatment of non-alcoholic steatohepatit...
2021-03-01 09:00
2638
Innovent Announces First Patient Outside China Dosed in the Phase 1 Clinical Trial of Anti-CD47/PD-L1 Bispecific Antibody
SAN FRANCISCO and SUZHOU, China, March 1, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2021-03-01 08:23
6118
Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index
SHANGHAI and HONG KONG, March 1, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncol...
2021-03-01 08:00
2686
Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index
SHANGHAI and HONG KONG, Feb. 28, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncol...
2021-03-01 08:00
5860
Week's Top Stories
Most Reposted
Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
[Picked up by 319 media titles]
2024-11-07 09:00
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
[Picked up by 313 media titles]
2024-11-12 09:00
DKSH Healthcare and Euris Unveil CRM & MCE Platform "ConnectPlus" to Revolutionize APAC Healthcare Distribution
[Picked up by 291 media titles]
2024-11-13 09:00
Sobot Introduces its All-in-One Solution at GITEX Global 2024
[Picked up by 289 media titles]
2024-11-12 11:00
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
[Picked up by 289 media titles]
2024-11-11 21:00
Most Read
Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
2024-11-07 09:00
10141
XtalPi and Sinar Mas Multiartha Launch Strategic Partnership to Revolutionize AI Across Asia-Pacific
2024-11-07 11:34
7500
XTEP's First Mono Store in Malaysia Comes to Puchong
2024-11-07 10:08
6214
